How to buy Unity Biotechnology stock (UBX)

Unity Biotechnology is a biotechnology business based in the US. Unity Biotechnology shares (UBX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.00 – an increase of 4.08% over the previous week. Unity Biotechnology employs 19 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Unity Biotechnology stock

Buy Unity Biotechnology stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Unity Biotechnology stock price (NASDAQ: UBX)

Use our graph to track the performance of UBX stocks over time.

Unity Biotechnology shares at a glance

• Key figures

Information last updated 2024-12-25.

Latest market close	$1.00
52-week range	$0.95 - $2.02
50-day moving average more info button	$1.22
200-day moving average more info button	$1.43
Wall St. target price	$7.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.28

Is it a good time to buy Unity Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Unity Biotechnology price performance over time

Historical closes compared with the close of $1.035 from 2024-12-26

1 week (2024-12-20)	7.83%
1 month (2024-11-27)	-14.46%
3 months (2024-09-27)	-28.62%
6 months (2024-06-28)	-23.33%

1 year (2023-12-28)	-45.81%
2 years (2022-12-28)	-60.65%
3 years (2021-12-28)	13.6
5 years (2019-12-27)	71.7

Unity Biotechnology financials

Gross profit TTM	$-35,223,000
Return on assets TTM	-30.34%
Return on equity TTM	-86.95%
Profit margin	0%
Book value	$0.84
Market Capitalization more info button	$16.9 million

TTM: trailing 12 months

Unity Biotechnology share dividends

We're not expecting Unity Biotechnology to pay a dividend over the next 12 months.

Have Unity Biotechnology's shares ever split?

Unity Biotechnology's shares were split on a 1:10 basis on 19 October 2022 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Unity Biotechnology shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Unity Biotechnology shares which in turn could have impacted Unity Biotechnology's share price.

Unity Biotechnology share price volatility

Over the last 12 months, Unity Biotechnology's shares have ranged in value from as little as $0.9468 up to $2.02. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Unity Biotechnology's is 0.827. This would suggest that Unity Biotechnology's shares are less volatile than average (for this exchange).

Unity Biotechnology overview

Unity Biotechnology, Inc. , a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.

Frequently asked questions

What percentage of Unity Biotechnology is owned by insiders or institutions?
Currently 1.309% of Unity Biotechnology shares are held by insiders and 20.546% by institutions. How many people work for Unity Biotechnology?
Latest data suggests 19 work at Unity Biotechnology. When does the fiscal year end for Unity Biotechnology?
Unity Biotechnology's fiscal year ends in December. Where is Unity Biotechnology based?
Unity Biotechnology's address is: 285 East Grand Avenue, South San Francisco, CA, United States, 94080 What is Unity Biotechnology's ISIN number?
Unity Biotechnology's international securities identification number is: US91381U1016 What is Unity Biotechnology's CUSIP number?
Unity Biotechnology's Committee on Uniform Securities Identification Procedures number is: 91381U101